MIAMI, December 2, 2015 -- Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will present a selection of the latest advances in hematology research at this year's American Society of Hematology (ASH) Annual Meeting, December 5-8, at the Orange County Convention Center in Orlando, Fla.
Reporters interested in interviewing Sylvester researchers on-site at the conference should contact Patrick Bartosch at (201) 469-6408 or firstname.lastname@example.org.
Highlights of research presented by Sylvester researchers include:
Monday, December 7
The small molecule Img-98, a potent and selective inhibitor of the lysine demethylase Lsd-1, effectively augments the pro-differentiation effects of all-trans-retinoic acid (ATRA) in a pre-clinical model of acute myeloid leukemia (AML)
Ronan Swords; presentation #460; 7:45 a.m.; W109, Level 1
Grb2 directly interacts with HGAL and ameliorates its effects on B-cell receptor signaling
Izidore Lossos; presentation #702; 4 p.m.; W311EFGH, Level 3
Saturday, December 5
Pharmacokinetics of red cell microparticles (RMP) in rabbits and rats: effects of administration, regimen and label of assay
Wenche Jy; poster #1146; 5:30-7:30 p.m.; Hall A, Level 2
Inhibition of the PI3K/AKT/mTOR pathway leads to down regulation of c-Myc and overcomes resistance to all-trans-retinoic acid (ATRA) in acute myeloid leukemia
Ronan Swords; poster #1363; 5:30-7:30 p.m.; Hall A, Level 2
The combination of belinostat with zidovudine for treatment of HTLV-I-related adult T-cell leukemia-lymphoma
Juan Carlos Ramos; poster #1562; 5:30-7:30 p.m.; Hall A, Level 2
Sunday, December 6
A patient-specific ex vivo screening platform for personalized acute myeloid leukemia (AML) therapy
Ronan Swords; poster #1352; 5:30-7:30 p.m.; Hall A, Level 2
The BET bromodomain inhibitors EP11313 and EP11336 have potent anti-leukemic activity in acute myeloid leukemia (AML) and augment the effects of all-trans-retinoic acid (ATRA) in vitro
Ronan Swords; poster #2552; 6-8 p.m.; Hall A, Level 2
Monday, December 7
Elevated red cell microparticles (RMP) in hematologic and thrombotic disorders
Wenche Jy; poster #3553; 6-8 p.m.; Hall A, Level 2
In acute myeloid leukemia (AML), targeting the histone methyltransferase EZH2 promotes differentiation, impairs clonogenic survival and augments the anti-leukemic effects of the retinoid, all-trans-retinoic acid (ATRA)
Ronan Swords; poster #3786; 5-8 p.m.; Hall A, Level 2
FBXO10 targets HGAL for degradation
Izidore Lossos; poster #3904; 6-8 p.m.; Hall A, Level 2
Join the conversation about this year's ASH Annual Meeting by using the hashtag #ASH2015 on Facebook, Twitter and Instagram.
About Sylvester Comprehensive Cancer Center
Sylvester Comprehensive Cancer Center, part of UHealth - the University of Miami Health System and the University of Miami Miller School of Medicine, is among the nation's leading cancer centers, and South Florida's only Cancer Center of Excellence. With the combined strength of more than 115 cancer researchers and 130 cancer specialists, Sylvester discovers, develops and delivers more targeted therapies leading to better outcomes - providing the next generation of cancer clinical care - precision cancer medicine - to each patient. Our comprehensive diagnostics coupled with teams of scientific and clinical experts who specialize in just one type of cancer, enable us to better understand each patient's individual cancer and develop treatments that target the cells and genes driving the cancer's growth and survival. At Sylvester, patients have access to more treatment options and more cancer clinical trials than most hospitals in the southeastern United States. To better serve current and future patients, Sylvester has a network of conveniently located outpatient treatment facilities in Miami, Kendall, Hollywood, Plantation, Deerfield Beach and Coral Springs, with plans to open in Coral Gables in 2016. For more information, visit sylvester.org.